Stonepine Capital Management LLC purchased a new stake in shares of Aytu BioPharma Inc. (NASDAQ:AYTU – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 912,921 shares of the company’s stock, valued at approximately $1,962,780. Aytu BioPharma accounts for approximately 0.0% of Stonepine Capital Management LLC’s portfolio, making the stock its 28th largest holding. Stonepine Capital Management LLC owned approximately 8.51% of Aytu BioPharma as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Dimensional Fund Advisors LP bought a new position in shares of Aytu BioPharma during the third quarter worth about $58,000. Two Sigma Investments LP increased its stake in Aytu BioPharma by 96.2% in the 3rd quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock worth $129,000 after acquiring an additional 33,701 shares during the last quarter. DRW Securities LLC bought a new position in Aytu BioPharma during the 4th quarter worth about $76,000. Rothschild Wealth LLC purchased a new stake in shares of Aytu BioPharma during the 4th quarter worth about $52,000. Finally, Persistent Asset Partners Ltd raised its position in Aytu BioPharma by 27.2% in the fourth quarter. Persistent Asset Partners Ltd now owns 79,415 shares of the company’s stock valued at $206,000 after purchasing an additional 16,963 shares during the period. 33.49% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several research firms recently commented on AYTU. Zacks Research raised shares of Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Monday, July 6th. Finally, Ascendiant Capital Markets increased their price target on Aytu BioPharma from $14.00 to $14.50 and gave the stock a “buy” rating in a research note on Thursday, June 11th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Aytu BioPharma has an average rating of “Hold” and a consensus price target of $10.75.
Aytu BioPharma Trading Up 0.4%
AYTU traded up $0.01 during midday trading on Friday, hitting $2.25. The company’s stock had a trading volume of 10,413 shares, compared to its average volume of 50,362. Aytu BioPharma Inc. has a 52-week low of $1.65 and a 52-week high of $3.07. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 0.27. The firm has a market cap of $24.14 million, a P/E ratio of -0.49 and a beta of 0.25. The firm has a 50-day moving average price of $2.24 and a two-hundred day moving average price of $2.36.
Aytu BioPharma Company Profile
Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.
Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.
Featured Stories
- Five stocks we like better than Aytu BioPharma
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
